___

• 1. Özkanlı SŞ, Zemheri IE, Yıldırm A, Gür HD, Balbay MD, Şenol S, Özkanlı AO, Alkan E, Zenginkinet T, Aydın A, Çaşkurlu T. Gleason score at the margin can predict biochemical recurrence afer radical prostatectomy, in addition to preoperative PSA and surgical margin status. Turk J Med Sci 2014; 44: 397–402.
• 2. Amling CL, Blute ML, Bergstralh EJ. Long-term hazard of progression afer radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure afer 5 years. J Urol 2000; 164: 101–105.
• 3. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancer-specifc survival following anatomic radical retropubic prostatectomy: the 15-year Johns Hopkins experience. Urol Clin North Am 2001; 28: 555–565.
• 4. Valicenti R K, Tompson I, Albertsen P,  Davis BJ,  Goldenberg SL,  Wolf JS, Sartor O, Klein OE, Hahn C, Michalski J et al. Adjuvant and salvage radiation therapy afer prostatectomy: American Society for Radiation Oncology/American Urological Association Guidelines. Int J Radiat Oncol Biol Phys 2013; 86: 822–828.
• 5. Bolla M, van Poppel H, Tombal B, Vekemans K, Da Pozzo L, de Reijke TM, Verbaeys A, Bosset JF, van Velthoven R, Colombel M et al. Postoperative radiotherapy afer radical prostatectomy for high-risk prostate cancer: long-term results of a randomized controlled trial (EORTC trial 22911). Lancet 2012; 380: 2018–2027.
• 6. Tompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer signifcantly reduces risk of metastases and improves survival: long-term follow-up of a randomized clinical trial. J Urol 2009; 181: 956–962.
• 7. NCCN Clinical Practice Guidelines in Oncology. Prostate Cancer V.I. 2014 http://www.nccn.org/professionals/ physician_gls/PDF/prostate.pdf.